Aspirin Therapy
Introduction to Aspirin Effects
- The American College of Chest Physicians recommends aspirin doses of 81-325 mg/day, which inhibits adenosine diphosphate (ADP) and collagen-induced platelet aggregation, blocks shear-dependent platelet aggregation, and reduces urinary thromboxane concentrations in a dose-dependent manner 1
- Approximately one-third of patients treated with aspirin demonstrate less-than-expected inhibition of platelet aggregation and increased levels of urinary thromboxane, according to the American College of Chest Physicians 1
Clinical Significance and Response Factors
- High platelet reactivity in aspirin-treated patients has been consistently associated with a 2-4 fold higher risk of myocardial infarction, stroke, or death, as reported by the American College of Chest Physicians 1
- Patient characteristics, such as age, female sex, and diabetes, as well as concomitant therapies, laboratory testing methods, and patient compliance, affect measured platelet reactivity, according to the American College of Chest Physicians and the Mayo Clinic Proceedings 1, 2
- Aspirin resistance may occur in approximately 5-60% of patients, depending on the definition and testing methods used, with mechanisms including poor medication adherence, accelerated platelet turnover in inflammatory states, genetic polymorphisms affecting COX-1, and drug interactions (e.g., NSAIDs blocking aspirin's access to COX-1) 2
Dosing and Drug Interactions
- A randomized, double-blind, cross-over trial with 125 coronary artery disease patients found that aspirin inhibited platelet aggregation in a dose-dependent manner at 81, 162, or 325 mg/day, as reported by the American College of Chest Physicians 1
- Most patients demonstrate near-complete inhibition of arachidonic acid-induced platelet aggregation with 81 mg/day, though higher doses may reduce the proportion of patients with suboptimal response, according to the American College of Chest Physicians 1
- Low-dose aspirin (75-100 mg daily) achieves complete inhibition of platelet COX-1 activity, preferentially inhibing COX-1 over COX-2, preserving some beneficial prostacyclin (PGI2) production, as recommended by the European Society of Cardiology and the American College of Chest Physicians 3, 1
- Meta-analyses of randomized trials demonstrate that low-dose aspirin (75-150 mg) is as effective as higher doses in preventing cardiovascular events, with once-daily dosing being effective due to irreversible COX-1 inhibition, as recommended by the American Heart Association 4, 1, 3
- Using higher doses of aspirin increases bleeding risk without additional benefit, as stated by the American College of Chest Physicians 1
- NSAIDs like ibuprofen can block aspirin's access to COX-1's active site, and this interaction occurs even with a once-daily regimen of ibuprofen, as reported by the Mayo Clinic Proceedings 2 and supported by 3
Platelet Turnover and Aspirin Inhibition
- Aspirin causes permanent inactivation of platelet cyclooxygenase-1 (COX-1) through acetylation, resulting in irreversible inhibition that lasts for the entire 8-10 day lifespan of the platelet, allowing for once-daily dosing despite aspirin's short half-life (approximately 20 minutes) 3
- The inactivation of COX-1 prevents the formation of prostaglandin endoperoxides and thromboxane A2 (TXA2), a potent platelet aggregator and vasoconstrictor, as supported by the European Society of Cardiology and the American Heart Association 3, 2
- In inflammatory states, newly formed platelets contain COX-2, which is less sensitive to aspirin inhibition, according to the Mayo Clinic Proceedings 2
- Ibuprofen causes reversible, competitive inhibition of COX-1, with effects that are transient, lasting only a short period after administration, and inhibits platelet COX-1 activity by only 70-90% when used at conventional anti-inflammatory doses 3
Special Considerations
- Patients with high cardiovascular risk derive greater absolute benefit from aspirin's antiplatelet effects, and in patients requiring both antiplatelet and anti-inflammatory therapy, alternative NSAIDs that don't interfere with aspirin's antiplatelet effect should be considered 1
- The European Heart Journal suggests that aspirin's antiplatelet effect persists for 7 days after the last dose due to irreversible inhibition, and only aspirin causes irreversible COX-1 inhibition, making it superior to ibuprofen for platelet inactivation 3
- The American College of Cardiology and the European Society of Cardiology support the use of low-dose aspirin (75-100 mg daily) for platelet inactivation, as it achieves complete inhibition of platelet COX-1 while minimizing side effects 3, 1
- Enteric-coated aspirin may result in slower absorption in acute settings, but this is not the primary concern, as noted by the European Society of Cardiology 5